STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)--Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in ...
STRASBOURG, France, MONTREAL and BOSTON, Oct. 28, 2025 Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for ...
BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its ...
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this ...
BEIJING, China & TOKYO--(BUSINESS WIRE)--February 1 st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (“LiberoThera”) ...
The MarketWatch News Department was not involved in the creation of this content. -- Recent publication of three international Patent Cooperation Treaty (PCT) patent applications covering Domain's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback